Pfenex (NYSEAMERICAN:PFNX) is set to post its quarterly earnings results after the market closes on Tuesday, March 13th. Analysts expect Pfenex to post earnings of ($0.49) per share for the quarter.
Pfenex (NYSEAMERICAN:PFNX) opened at $4.34 on Monday. Pfenex has a 12-month low of $2.07 and a 12-month high of $7.43. The firm has a market cap of $106.11, a PE ratio of -2.44 and a beta of 3.60.
Separately, Zacks Investment Research downgraded shares of Pfenex from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th.
WARNING: “Pfenex (PFNX) to Release Quarterly Earnings on Tuesday” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3256325/pfenex-pfnx-to-release-quarterly-earnings-on-tuesday.html.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.